tbuckley/cabot-search huggingface dataset:
Abstract 20944: Perivascular Progenitor Cells Contribute To Neointima Formation After Wire-induced Injury
Authors: Jan-Marcus Daniel, Wiebke Bielenberg, Philipp Stieger, Harald Tillmanns, Daniel Sedding
Journal: Circulation (2010)

Bone marrow-derived progenitor cells (BMPCs) as well as perivascular progenitor cells have been implicated to differentiate into vascular cells during neointima formation. The objective of this study was to assess the contribution of progenitor cells to the cellular neointimal mass. Wire-induced injury of the femoral artery was performed on chimeric C57BL/6 mice transplanted with bone marrow from transgenic mice expressing enhanced green fluorescence protein (EGFP). Vessels were harvested at 1, 2, 4, 6 and 16 weeks after dilation (n=8 animals per time point) and analyzed using confocal microscopy. Most of the accumulating EGFP+-cells were identified as inflammatory cells (CD45, CD68), and their number in the neointima declined from 110.81±18.98 at 2 weeks to only 5.31±2.21 at 16 weeks after dilation. Whereas very few EGFP+-cells co-expressed α-smooth muscle actin or CD31, expression of smooth muscle myosin heavy chain or von Willebrand Factor was not detected in BM-derived cells at any time point. Interestingly, a substantial expression of stem cell antigen (Sca)-1 was detected in proliferating EGFP negative cells in the adventitial layer, but only a small fraction of BM-derived cells accumulating at the arterial lesion site co-expressed Sca−1. At 4 weeks after dilation, the absolute number of adventitial Sca-1+-cells increased from 47.88±7.18 cells/slide in non-injured arteries to 158.5±16.656 cells/slide and the fraction of proliferating cells rose to 14.94% of all adventitial cells. Even though recent in vitro data have shown that perivascular progenitor cells lose Sca-1 from their cell surface when differentiating into smooth muscle-like cells, we also detected singular Sca-1+/EGFP--cells within the neointimal lesion, indicating that these cells indeed migrate toward the luminal site. In conclusion, we provide evidence that BMPCs within the neointima rarely co-express markers for vascular cells and do not contribute to the neointimal cellular mass beyond the inflammatory response. In contrast, the high proliferation rates of perivascular progenitor cells indicate a possibly substantial contribution of this cell fraction to the development of the neointimal lesion.
P257 Understanding the effects on lung function of chest binder use in the transgender population
Authors: RJM Cumming, K Sylvester, J Fuld
Journal: Thorax (2016)

<h3>Introduction</h3> Chest binders are garments used for compression of breast tissue by transgender individuals. Deleterious consequences of binder reported include shortness of breath with associated reduced exercise tolerance and speech difficulties; some have suggested lung function is monitored in users of chest binders.<sup>1</sup> We conducted a study to investigate any respiratory deficits caused by chest binders as currently used in the transgender population. <h3>Methods</h3> We recruited 20 participants from the transgender community. All were assigned female at birth. Ages ranged from 19–47 with median age 22; 4 were current smokers and 4 had mild to moderate asthma. All were habitual users of chest binders. Participants underwent spirometry testing and measures of chest circumference and posture with and without their own binder. The order of testing with or without the binder was random. Ethics approval was granted by the University of Cambridge. <h3>Results</h3> Table 1 shows abnormal baseline lung function. The median FEV1/FVC is abnormally high but not acutely influenced by the binder. The standard residual of all forced spirometric values was significantly (p &lt; 0.001) below predicted values (based on sex assigned at birth); peak expiratory flow (PEF) values were also lower than predicted. There was a significant reduction in expiratory vital capacities, both SVC and FVC (p &lt; 0.01) when the binder was on but no other significant acute change. On average chest circumference was reduced by the binder. There was no average change in thoracic kyphosis due to high variability. <h3>Conclusions</h3> Transgender individuals using chest binders have abnormal lung function. The acute effect of wearing the binder appears to be an overall volume reduction with little other change. Abnormal lung function in the population may indicate a chronic effect of binder usage or generally poor respiratory health. However, due to the small size and timeframe of the study no control population was tested and thus a systematic error cannot be ruled out. <h3>Reference</h3> Davies S, Papp VG, Antoni C. Voice and communication change for gender nonconforming individuals: Giving voice to the person inside. <i>Int J Transgenderism </i> 2015;<b>16</b>:117–159.
Studies on the Effect of Low Oxygen Gas Inhalation on the Renal Circulation and Electrolyte Metabolism in Patients with Diabetes Mellitus
Authors: Mitsuo Yoshinaka
Journal: Circulation (1969)

Among the causes of death by diabetes mellitus in recent years, vascular disturbrance has been increased and especially, diabetic nephropathy has drawn our attention. Studies on this diabetic nephropathy have been done on various aspects. However, most of them were based on the examinations at resting state. Therefore, the author examined the reactivity of renal circulation and electrolyte metabolism against stress produced by inhalation of low oxygen gas on patients with diabetes mellitus. Method and Meterials Method The standard renal clearance methods were employed simultaneously while 10 per cent O2 inhalation was carried out. Before and after the low oxygen gas inhalation, determinations of renal circulation and electrolyte metabolism. Materials 41 patients with diabetes mellitus, age from 18 to 78, 24 men and 17 women. The subjects were classified as follow: (i) Existence of urine protein. (ii) Existence of urine sugar. (iii) Blood sugar: (a) under 139 mg/dl, (b) over 140 mg/dl: (vi). Blood pressure: (a) Normal type, systolic pressure under 149 mmHg and diastolic pressure under 89 mmHg, (b) Old age type, systolic pressure under 149 mmHg and diastolic pressure over 90 mmHg systolic pressure, over 150 mmHg and diastolic pressure under 89 mmHg, (c) Essential type, systolic pressure over l 50 mmHg and diastolic pressure over 90 mmHg; (v) Eye ground: (a) normal group, under KW I, (b) Abnormal group, over KW II; (vi) Duration (a) under 5 years, (b) over 5 years; (vii) Age: (a) under 39 years old, (b) 40 to 59 years old, (c) over 60 years old; (viii) Renal blood flow in the resting state: (a) over 760 cc/min, (b) 759 cc/min-480 cc/min, (c) under 479 cc/min. Result and Comments A. In room air inhalation. (1) Renal circulation. RBF of patients with diabetes mellitus, as compared with normal adults, has shown slightly low in general. In the study of this decrease of renal circulation by classification of clinical symptoms, it was proved with the abnormal eye ground group and the group of patients with diabetes mellitus over 5 years.
P3.03-035 Prognostic Role of hENT1 and RRM1 in Patients with Advanced Pleural Mesothelioma Treated with Second Line Gemcitabine Based Regimens
Authors: Andrés Cardona, Oscar Arrieta, Leonardo Rojas, Luis Corrales, Beatriz Wills, George Oblitas, Ludwing Bacon, Claudio Martin, Mauricio Cuello, Luis Mas, Carlos Vargas, Hernan Carranza, Jorge Otero, Maria Perez, Lisde González, Luis Chirinos, Rafael Rosell
Journal: Journal of Thoracic Oncology (2017)
S100 Cumulative distribution of patients by change in FVC% predicted in the inpulsis® trials of NINTEDANIB in patients with idiopathic pulmonary fibrosis
Authors: U Costabel, KR Flaherty, KK Brown, W Stansen, R Schlenker-Herceg, G Raghu
Journal: Thorax (2016)

<h3>Introduction</h3> The two 52-week Phase III INPULSIS® trials assessed the efficacy and safety of nintedanib in patients with IPF. In both trials, nintedanib significantly reduced the annual rate of decline in forced vital capacity (FVC) versus placebo. <h3>Methods</h3> We assessed the cumulative distribution of patients by absolute changes from baseline to week 52 in FVC% predicted using thresholds of ≥0%, ≥5% and ≥10% in the individual INPULSIS® trials and pooled data. Missing data (due to death, loss to follow-up, or censoring before week 52) were imputed using the worst decline from baseline at week 52 observed in all patients with available data regardless of treatment. <h3>Results</h3> 1061 patients were treated in the INPULSIS® trials (n = 638 nintedanib; n = 423 placebo). In INPULSIS®−1, a smaller proportion of patients treated with nintedanib than placebo had any decline in FVC% predicted (absolute decline in FVC ≥ 0% predicted) (71% versus 82%; p = 0.002), an absolute decline in FVC ≥ 5% predicted (47% versus 62%; p = 0.001) and an absolute decline in FVC ≥ 10% predicted (29% versus 43%; p &lt; 0.001) from baseline to week 52 based on the cumulative distribution of patients. In INPULSIS®−2, a smaller proportion of patients treated with nintedanib than placebo had any decline in FVC% predicted (70% versus 88%; p &lt; 0.001), an absolute decline in FVC ≥ 5% predicted (47% versus 61%; p = 0.001) and an absolute decline in FVC ≥ 10% predicted (30% versus 36%; p = 0.18) from baseline to week 52. In pooled data, the proportions of patients treated with nintedanib and placebo, respectively, who had any decline in FVC ≥ 0% predicted, an absolute decline in FVC ≥ 5% predicted and an absolute decline in FVC ≥ 10% predicted were 70% versus 85% (p &lt; 0.001), 47% versus 61% (p &lt; 0.001) and 30% versus 39% (p &lt; 0.001) (Figure). The proportion of patients with no decline or an improvement in FVC% predicted were 30% in the nintedanib group versus 15% in the placebo group. <h3>Conclusion</h3> In the INPULSIS® trials, a higher proportion of patients with IPF treated with nintedanib than placebo had no decline or an improvement in FVC. Smaller proportions of patients had absolute declines in ≥5% and ≥10% predicted over 52 weeks.
S109 Targeting the prostacyclin pathway in the treatment of connective tissue disease associated pulmonary arterial hypertension (pah): insights from the randomised controlled griphon trial with selexipag
Authors: G Coghlan, S Gaine, R Channick, L Di Scala, N Galiè, HA Ghofrani, MM Hoeper, I Lang, V McLaughlin, R Preiss, LJ Rubin, G Simonneau, O Sitbon, VF Tapson, K Chin
Journal: Thorax (2016)

<h3>Rationale</h3> Despite available therapies, patients with connective tissue disease-associated PAH (PAH-CTD) have a poor prognosis. The global phase III GRIPHON study (NCT01106014) enrolled 1,156 patients including 334 with PAH-CTD. Compared with placebo, selexipag reduced the risk of the primary composite outcome of morbidity/mortality up to end of treatment by 41% (hazard ratio [HR] 0.59; 99% CI: 0.37–0.96) among patients with PAH-CTD. We examined the effect of selexipag vs placebo in the PAH-CTD subgroups: PAH associated with systemic sclerosis (PAH-SSc), systemic lupus erythematous (PAH-SLE) and mixed CTD (PAH-MCTD). <h3>Methods</h3> Patients (18–75 years) were randomised 1:1 to placebo or selexipag. HRs (95% CI) were calculated using Cox regression models to determine the effect of selexipag vs placebo on morbidity/mortality. <h3>Results</h3> Of the 334 patients enrolled with PAH-CTD, 170 had PAH-SSc, 82 PAH-SLE, and 47 PAH-MCTD; CTD sub-classification was not reported in 35 patients. Across the subgroups, the majority of patients were female (84–99%) and were receiving an endothelin receptor antagonist, a phosphodiesterase type-5 inhibitor or both at baseline (73–83%). In the PAH-SSc, PAH-SLE and PAH-MCTD subgroups, the mean (SD) age was 60.0 (10.6), 39.0 (11.3) and 48.0 (14.7) years, respectively, and 65%, 33%, and 45% were in WHO functional class III, respectively. Selexipag reduced the risk of morbidity/mortality events by 44% (HR 0.56; 95% CI: 0.34–0.91) in PAH-SSc, 34% (HR 0.66; 95% CI: 0.30–1.48) in PAH-SLE, and 53% (HR 0.47; 95% CI: 0.15–1.48) in PAH-MCTD (Figure). The treatment effect was consistent across the subgroups (interaction test indicated no heterogeneity; p = 0.6737). By the end of study, 22 PAH-SSc, 7 PAH-SLE and 3 PAH-MCTD patients in the placebo, and 17 PAH-SSc, 4 PAH-SLE, 8 PAH-MCTD patients in the selexipag group had died. Common prostacyclin-associated side effects observed with selexipag in PAH-CTD patients generally occurred at a similar incidence to PAH-non-CTD patients and within the PAH-CTD subgroups. <h3>Conclusion</h3> GRIPHON included the largest randomised cohort of patients with PAH-CTD to date. The treatment effect of selexipag on time to first morbidity/mortality event was consistent across the subgroups, suggesting that selexipag is an effective therapeutic option in these difficult-to-treat patients. Please refer to page A270 for declarations of interest in relation to abstract S109.
P1.08-041 Disease Free and Overall Survival is Equal in Open and VATS Resection for Early Lung Cancer in a Multivariate Analysis
Authors: Caecilia Ng, Florian Kocher, Herbert Maier, Magdalena Sacher, Gregor Laimer, Michael Fiegl, Paolo Lucciarini, Thomas Schmid, Florian Augustin
Journal: Journal of Thoracic Oncology (2017)
Robert C. Bailey, Stephen Moses, Corette B. Parker, Kawango Agot, Ian Maclean, John N. Krieger, Carolyn R.M. Williams, Richard T. Campbell, Jeckoniah O. Ndinya-Achola. A Randomized Controlled Trial of Male Circumcision to Reduce HIV Incidence in Kisumu, K
Authors: J O Ndinya-Achola
Journal: The Lancet (2007)
Release of Microparticles During Blood Storage Is Influenced by Residual Platelets, Leukocytes and Oxygen Levels
Authors: Wenche Jy, Carlos J Bidot, Tatsuro Yoshida, Ralph Vassallo, Max E Johansen, Lawrence L Horstman, John Morgan, Orlando Gomez-Marin, Sherry Shariatmadar, Yeon S Ahn
Journal: Blood (2012)
Does Previous Interferon Use Have Negative Effect on Imatinib Response in Chronic Myeloid Leukemia (CML)? A Single Center Study.
Authors: Mustafa Yenerel, Reyhan Diz-Kucukkaya, Naciye Demirel, Mesut Ayer, Selim Yavuz, Sevgi Besisik, Melih Aktan, Meliha Nalcaci, Deniz Sargin, Tanju Atamer, Yuksel Pekcelen, Guncag Dincol
Journal: Blood (2006)
Ex Vivo Experiments Show That IDH1/2-Mutant Inhibitors Can be Safely Used As Adjuvants to Regular Chemotherapy in IDH1/2-Mutated Acute Myeloid Leukemia
Authors: Remco Molenaar, Bhumika J. Patel, Mohammed Khurshed, Bartlomiej Przychodzen, Srinivasa Reddy Sanikommu, Hetty E. Carraway, Tomas Radivoyevitch, Hideki Makishima, Cornelis J van Noorden, Jaroslaw P. Maciejewski
Journal: Blood (2015)
P2.03b-038 The Diagnostic and Prognostic Value of CSF Cyfra 21-1 in Patients with Leptomeningeal Metastasis of Non-Small Cell Lung Cancer
Authors: Jae-Won Hyun, Su-Hyun Kim, Sang-Hyun Hwang, Ho-Shin Gwak, Ho Jin Kim
Journal: Journal of Thoracic Oncology (2017)
Toxicity of <sup>131</sup>I-MIBG combined with high-dose chemotherapy in children with refractory neuroblastoma.
Authors: L. Amoroso, G. Villavecchia, M. Cabria, A. Piccardo, M. Conte, M. Nantron, A. Garaventa, B. De Bernardi
Journal: Journal of Clinical Oncology (2011)

9549 Background: More effective regimens with acceptable toxicity are needed to improve prognosis of children with high-risk neuroblastoma. Iodine-131–metaiodobenzylguanidine (131I-MIBG) has been used for targeted radiotherapy of neural crest tumors, including neuroblastoma. By this retrospective study, we have evaluated feasibility and toxicity of 131I-MIBG combined to myeloablative chemotherapy (HD-CHT) with peripheral blood stem cell (PBSC) rescue in children with refractory neuroblastoma. Methods: Between October 1983 and October 2005 a total of 53 patients with refractory neuroblastoma received therapeutic 131I-MIBG combined with HD-CHT. Patients were divided in 2 cohorts. First cohort (FC) patients (n=34) received 131I-MIBG before HD-CHT. Second cohort (SC) patients (n=19) received 131I-MIBG after HD-CHT. Median age at diagnosis was 39 months (range, 7-198). FC patients received 131I-MIBG at the median dose of 7.26 mCi/kg (range, 3.75-16.66), at 16-45 days (median, 20) before HD-CHT. SC patients received 131I-MIBG at the median dose of 6 mCi/kg (range, 2.28-10), at 27-103 days (median, 57) after HD-CHT. Ten types of regimens were used as HD-CHT. Results: Both 131I-MIBG infusion and HD-CHT were well tolerated. Hematologic toxicity was comparable for the 2 cohorts. Median times to neutrophil (>0.5 x 103/µL) and platelet (> 50 x 103/µL) engraftment were 13 days (range, 8-30) and 21 days (range, 12->60), respectively. The predominant non hematopoietic toxicity was oral mucositis, of grade 4 in 23 patients (16 in the FC and 7 in the SC patients) and grade 3 in 9 (3 in the FC and 6 in the SC). Pulmonary complications occurred in 2 children. The predominant long-term toxicity was hypothyroidism which occurred in 9 FC and 6 SC patients. Conclusions: Treatment with 131I-MIBG in combination to HD-CHT was feasible with acceptable toxicity. Future studies are warranted to evaluate the efficacy of this combination.
P3.02c-085 Neutrophil/Lymphocyte Ratio in Advanced Non-Small Cell Lung Cancer: Correlation with Prognosis and Response to Anti-PD1 Therapy
Authors: Domenico Galetta, Antonio Fabio Logroscino, Andrea Misino, Elisabetta Sara Montagna, Patrizia Petrillo, Donata Ricci, Annamaria Catino
Journal: Journal of Thoracic Oncology (2017)
Clinical Features and Prognosis of MDS Patients with Chromosome 5 Abnormalities Other Than ‘5q-Syndrome’: Results of Multi-Center Analysis in Korea.
Authors: June-Won Cheong, Inho Kim, Sung-Soo Yoon, Dong Soon Lee, Chul Won Jung, Jin Seok Ahn, Kihyun Kim, Sun Hee Kim, Eul-Ju Seo, Chan-Jeoung Park, Hyun-Sook Chi, Sung-Hyun Kim, Hyuk-Chan Kwon, Hyo-Jin Kim, Hyeoung Joon Kim, Jae Sook Ahn, Hoon Kook, Ho-Jin Shin, Joo Seop Chung, Mark Hong Lee, Hwi-Joong Yoon, Sung Hwa Bae, Yong-Dong Joo, Dae Sik Hong, Soo-Mee Bang, Chul Soo Kim, Deog-Yeon Jo, Dae Young Zang, Doh Yu Hwang, Jin Seok Kim, Yoo-Hong Min
Journal: Blood (2007)
Primary Failure of Platelet Recovery Is the Foremost Prognostic Factor after Allogeneic Stem Cell Transplantation Following Myeloablative Conditioning for Myelodysplastic Syndrome: A Study from the SFGM-TC
Authors: Jordan Gauthier, Gandhi Damaj, Marie Robin, Nathalie Contentin, Yves Beguin, Eric Deconinck, Anne Huynh, Stephane Vigouroux, Patrice Chevalier, Hélène Labussière-Wallet, Felipe Suarez, Mohamad Mohty, Ibrahim Yakoub-Agha
Journal: Blood (2015)
A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia
Authors: Richard Derman, Eloy Roman, Manuel R. Modiano, Maureen M. Achebe, Lars L. Thomsen, Michael Auerbach
Journal: American Journal of Hematology (2017)

Abstract Iron deficiency anemia (IDA) is common in many chronic diseases, and intravenous (IV) iron offers a rapid and efficient iron correction. This trial compared the efficacy and safety of iron isomaltoside (also known as ferric derisomaltose) and iron sucrose in patients with IDA who were intolerant of, or unresponsive to, oral iron. The trial was an open‐label, comparative, multi‐center trial. Five hundred and eleven patients with IDA from different causes were randomized 2:1 to iron isomaltoside or iron sucrose and followed for 5 weeks. The cumulative dose of iron isomaltoside was based on body weight and hemoglobin (Hb), administered as either a 1000 mg infusion over more than 15 minutes or 500 mg injection over 2 minutes. The cumulative dose of iron sucrose was calculated according to Ganzoni and administered as repeated 200 mg infusions over 30 minutes. The mean cumulative dose of iron isomaltoside was 1640.2 (standard deviation (SD): 357.6) mg and of iron sucrose 1127.9 (SD: 343.3) mg. The primary endpoint was the proportion of patients with a Hb increase ≥2 g/dL from baseline at any time between weeks 1‐5. Both non‐inferiority and superiority were confirmed for the primary endpoint, and a shorter time to Hb increase ≥2 g/dL was observed with iron isomaltoside. For all biochemical efficacy parameters, faster and/or greater improvements were found with iron isomaltoside. Both treatments were well tolerated; 0.6% experienced a serious adverse drug reaction. Iron isomaltoside was more effective than iron sucrose in achieving a rapid improvement in Hb. Furthermore, iron isomaltoside has an advantage over iron sucrose in allowing higher cumulative dosing in fewer administrations. Both treatments were well tolerated in a broad population with IDA.
Occupational lung diseases: from old and novel exposures to effective preventive strategies
Authors: Paul Cullinan, Xavier Muñoz, Hille Suojalehto, Raymond Agius, Surinder Jindal, Torben Sigsgaard, Anders Blomberg, Denis Charpin, Isabella Annesi-Maesano, Mridu Gulati, Yangho Kim, Arthur L Frank, Metin Akgün, David Fishwick, Rafael E de la Hoz, Subhabrata Moitra
Journal: The Lancet Respiratory Medicine (2017)
P2.03a-010 A Randomized Phase II Study of Platinum-Based Chemotherapy +/- Metformin in Chemotherapy-Naïve Advanced Non-Squamous NSCLC
Authors: Kristen Marrone, Patrick Forde, Julie Brahmer, Gary Rosner, Xian Zhou, Barbara Coleman, David Ettinger
Journal: Journal of Thoracic Oncology (2017)
P2.01-070 Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Authors: Nicola Wyatt, Linda Hogarth, Dianne Turner, Miranda Patterson, David Jamieson, Fiona Black, Claire Hutton, Paula Mulvenna, Tim Simmons, Alexander Bradshaw, Claire Kolenda, Craig Parker, Carmen Martin-Ruiz, Alastair Greystoke
Journal: Journal of Thoracic Oncology (2017)
Analysis of the Crosstalk Between TGF-β–VEGF-Angiogenesis in an In Vivo Model of Acute Promyelocytic Leukemia
Authors: Patricia Aparecida Assis, Lorena Lobo Figueiredo Pontes, Antonio Roberto Lucena Araújo, Aglair Bergamo Garcia, Roberto P. Falcao, Fernando Chahud, Arnon Nagler, Eduardo M. Rego
Journal: Blood (2010)
P2.06-011 Phase 2 Study of MM-121 plus Chemotherapy vs. Chemotherapy Alone in Heregulin-Positive, Locally Advanced or Metastatic NSCLC
Authors: Lecia Sequist, Ian Anderson, Akin Atmaca, Todd Bauer, Young Chae, Haiying Cheng, Manuel Cobo, Nate Demars, Enriqueta Felip, Nikolaj Frost, Ramón García Gómez, Jhanelle Gray, Wael Harb, Leora Horn, Rudolf Huber, Dolores Isla, Arthur Kudla, Jean Lee, Sara Mathews, Ranee Mehra, Manuel Modiano, Jorge Nieva, Joseph Rosales, Frances Shepherd, Alexander Spira, Akos Czibere
Journal: Journal of Thoracic Oncology (2017)
P2.03a-037 Prognosis of Advanced Non-Small Cell Lung Cancer (NSCLC) Refractory to First-Line Platinum Chemotherapy
Authors: Hee Kyung Ahn, Young Saing Kim, Eun Young Kim, Sun Young Kyung, Shin Myung Kang, Eun Kyung Cho
Journal: Journal of Thoracic Oncology (2017)
P1.05-051 Safety and Compliance Data of the Phase III Study of Adjuvant Chemotherapy in Completely Resected P-Stage I Non-Small Cell Lung Cancer: JCOG0707
Authors: Hideo Kunitoh, Hiroyuki Sakurai, Masahiro Tsuboi, Masashi Wakabayashi, Morihito Okada, Kenji Suzuki, Norihiko Ikeda, Mitsuhiro Takenoyama, Yasuhisa Ohde, Makoto Takahama, Katsuo Yoshiya, Isao Matsumoto, Motohiro Yamashita, Takashi Marutsuka, Hiroshi Date, Yasuki Saito, Yoshinori Yamashita, Norihito Okumura, Shun-Ichi Watanabe, Hisao Asamura
Journal: Journal of Thoracic Oncology (2017)